click enter text
outlook answer question
start tmo outlook absorb margin pressur contract
transit commerci org reinvest take conserv tact
top line still bracket ep consensu benefit
tax rate declin buy-back oper call in-lin
stock expect higher catalyst howev carri
burden expect set stock enter day
averag premium tool agil
investor expect anoth year beat/rais
debat remain polar remain data-depend latest
data continu us suggest tool compani under-index pure
life science/biolog greater risk slow
thought china carri big-ticket equip exposur less
china growth deceler lsd roughli
plan given tough comp guid china deceler
comp-adj quarter capit spend paus industrial/acad-gov
hardwar state-fund entiti key pressur potenti neg
read-through nano management commentari biopharma
diagnost remain bullish expect continu biolog lab
expans demand servic neither includ
estim headwind china coronaviru
bridg ep organ guidanc cut growth
analyt instrument china acad-gov/industri hardwar weak
life solut minor decel bioprocess post latest
capital-expenditure outlook review overal cut organ growth organ
omx remain year remov royalti concess one-
time reinvest re-financ windfal rais ep estim
cut pt yield
key learn tmo china exposur hc/dx global
averag potenti insul coronavirus-rel dynam
brammer accret china fund slowdown
industrial/acad-gov hardwar concentr state own
enterpris budget fund current
order withdrawn notabl lack evid
budget flush in-lin pki ep commentari
trade fundament data
upsid target
price market close
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
result wolf model chang
exhibit annual guidanc tracker
exhibit premium multipl
page
mncurrent qconsensusorgan impactestimateactu changeanalyt bp life organ bp laboratori product organ bp specialti organ bp excl adj gross oper incom interest incom net incom dilut share gross bpsoper bpseffect tax bp net bpsvarianc estimate prior yearannu guidanc growthgross margin flat gm margin tax ep dilut sale fx adj ep dil share share net price-to-earnings premium price-to-earnings
note base busi exclud growth fei pthn bioprocess bioscienc sub-divis
page
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool price-to-earnings premium compound-annual-growth-rate price-to-earnings premium tool median median median
note figur million unless state per-shar term
page
excl deal relat share fulli ebit increment
note figur million unless state per-shar term
page
